Can lactoferrin modulate the immunostimulant activity of levamisole in rats by Wafaa Abdou Mohamed Mohamed
48
Department of Clinical Pathology, Faculty of Veterinary Medicine, Zagazig University, 44511 Zagazig, Egypt
Correspondence: Wafaa Abdou Mohamed Mohamed, 
Dept. Clinical Pathology, Faculty of Veterinary, Zagazig University, 44511 Zagazig, Egypt.     Email: waffa.clinical@yahoo.com
Received: 20.12.2013,  Accepted: 27.02.2014
Copyright © JCEI / Journal of Clinical and Experimental Investigations 2014, All rights reserved
JCEI /   2014; 5 (1): 48-53
Journal of Clinical and Experimental Investigations   doi: 10.5799/ahinjs.01.2014.01.0358
ORIGINAL ARTICLE / ÖZGÜN ARAŞTIRMA
Can lactoferrin modulate the immunostimulant activity of levamisole in rats 
immunosuppressed by cyclophosphamide?
Laktoferrin siklofosfamid ile immunsuprese ratlarda levamizol’un immün stimulan etkisini 
düzenleyebilir mi?
Wafaa Abdou Mohamed Mohamed
ÖZET
Amaç: Bu çalışmanın amacı immunsuprese rat modelin-
de laktoferrin kullanılarak levamizolün immün düzenleyici 
aktivitesini araştırmaktır.
Yöntemler:  Çalışma  planı:  Çalışmada  14  haftalık  140 
erkek albino rat (250-280 g) kullanıldı. Ratlar herbirinde 
20 rat bulunan 7 gruba ayrıldı. Birinci grup Kontrol grubu, 
Grup  II’ye  siklofosfamid  tek  intraperitoneal  dozda  (250 
mg),  Grup  III  siklofosfamid  ve  laktoferrin  verilen  grup, 
Grup IV oral içme suyu içinde sadece Laktoferrin (%0,5) 
verilen grup; Grup V siklofosfamid ve levamizol ile teda-
vi edildi, Grup VI’ya oral levamizol (2,5 mg/kg) verildi ve 
GrupVII’ye laktoferrin, siklofosfamid ve lavamizol verildi. 
Hayvanlar  feda  edildi  ve  çalışmanın  başlamasını  takib 
eden 21. Günde iki farklı kan örneği alındı ve total ve 
ayırıcı lökosit sayısı, serum total proteinleri, albümin, alfa 
globülin, beta globülin, gama globülin, nitrik oksit üretimi 
ve lizozim aktivitesi ölçüldü.
Bulgular:  Siklofosfamid  grubunun  yukarıda  bahsedilen 
parametrelerinde  anlamlı  düşüş  gözlendi  ki  bu  durum 
hem laktoferrin hem de levamizol verilmesi ile düzeldi.
Sonuç: Bu çalışmamızda siklofosfamid ile immunsupre-
se edilen ratlarda laktoferrinin levamizolün immunstimu-
lan etkisini iyileştirdiği sonucuna varıldı.
Anahtar kelimeler: Sığır laktoferrini, Levamizol, Siklofos-
famid, Immunmodülasyon, Lizozim deneyi
ABSTRACT
Objective: The aim of this study was to study the immu-
nomodulatory activity improvement of levamisole by using 
lactoferrin when applied to immunosuppressed rat model. 
Methods: The study was designed as follows, 140 male 
albino rats (250-280 g) 14 weeks old were used in our 
work. Rats were randomly divided into seven groups, 20 
in each. The group I was kept as a control, group II was 
given cyclophosphamide (CYP) at a single intraperitoneal 
dose of (250 mg/kg body weight), group III CYP and lac-
toferrin (Lac) treated group, group IV orally administrated 
Lac only (0.5%) in drinking water, group V treated with 
CYP and levamisole, group VI administrated levamisole 
orally at a dose of (2.5 mg/kg body weight) and group VII 
was given CYP, Lac and levamisole. Animals were sac-
rificed and two separate blood samples were collected 
after 21 days from the beginning of the experiment for 
measuring the total and differential leukocyte count, se-
rum total proteins, albumin, alpha globulin, beta globulin 
and gamma globulin, Nitric oxide (NO) production and ly-
sozyme activity.
Results: CYP group showed significant decrease in the 
above mentioned parameters, which were improved after 
administration of both lactoferrin and levamisole. 
Conclusion:  Our  study  concluded  that  lactoferrin  im-
prove the immunostimulant effect of levamisole in CYP- 
immunosuppressed rats. J Clin Exp Invest 2014; 5 (1): 
48-53
Key words:  Bovine  lactoferrin  (Lac),  Levamisole  , 
Cyclophosphamide(CYP), Immunomodulation, Lysozyme 
assay
INTRODUCTION
Immunostimulants are agents that trigger the non-
specific immune response and result in enhanced 
disease resistance. Several compounds have been 
reported  to  have  immunostimulation  properties. 
Many of these are derivatives or cellular compo-
nents of bacterial, fungal or animal origin such as 
laminarin,  barley,  glucan,  lactoferrin,  levamisole, 
lipopolysaccharides,  curdlan,  scleroglucan,  zymo-
san, inulin, chitosan, glucans, dextran, lentinan, sa-
ponins, herbal extracts, peptidoglycans [1].Mohamed. Effect of lactoferrin on immunostimulant activity of levamisole  49
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Cyclophosphamide  (CYP)  is  an  alkylating 
agent widely used as cancer chemotherapy and au-
toimmune disease therapy [2]. CYP is a well-known 
and powerful immunosuppressive agent with dose-
specific effects. Low dose of CYP acts mainly on 
B cell regions in lymphoid organs, but high doses 
have an effect upon both B and T cell regions [3].Le-
vamisole is mainly used as an anthelmintic agent in 
veterinary purpose [4] but in some countries, its use 
is limited to immunomodulatory agent in humans in 
some cancers. It is having an immunostimulating ef-
fect in immunosuppressed condition [5] but it has 
been found that it is also having a useful effect in 
autoimmune diseases like nephrotic syndrome and 
rheumatoid arthritis. It helps to make steroid free 
period of up to 6 months to 1 year in nephrotic syn-
drome [6,7].
Lactoferrin (Lac) is an 80 kDa multifunctional 
glycoprotein belonging to the transferrin family. Lac 
is primarily present in milk, and is also found in oth-
er biological fluids, such as saliva, tears, bile and 
pancreatic juice [8]. It has been widely documented 
that Lac displays antimicrobial activity against many 
different pathogenic agents. This activity was attrib-
uted to its ability, to bind iron with a high affinity and 
unlike transferrin, retain its bound iron under acidic 
conditions. Lac is considered to be a part of the in-
nate immune system and takes part in specific im-
mune reactions, but in an indirect way [9].Lac has a 
wide range of effects on the immune system, both 
in vivo and in vitro [10]. Lactoferrin is a cell-secreted 
mediator that bridges innate and adaptive immune 
function  in  mammals.  It  is  a  pleiotropic  molecule 
that directly assists in the influence of presenting 
cells for the development of T-helper cell polariza-
tion [11]. 
The objective of the present research work is to 
check the effect of to study the improvement of the 
levamisole  immunomodulation  action  when  given 
with lactoferrin.
METHODS
Animals
140 male albino rats (250-280 g) 14 weeks old were 
obtained  from  the  faculty  of  Veterinary  Medicine, 
Zagazig University to use for the study. The rats 
were distributed in seven groups, housed in solid-
bottomed cages containing bedding of wood shav-
ings and were allowed food and water ad libitum. 
The room temperature was maintained at 21-24°C, 
and a 12 h light/dark cycle was employed. All ani-
mals were acclimatized for 1 week before starting 
the  experiment.  The  ethical  standards  guidelines 
for the care and use of laboratory animals provided 
by the animal ethics committee (institutional or na-
tional) and with the Committee for the Purpose of 
Control and Supervision of Experiments on Animals 
(CPCSEA) were used.
Chemicals
Immunostimulant  agent  (levamisole  10%)  levami-
sole hydrochloride (pharma sewede,Egypt).Bovine 
lactoferrin was purchased from Sigma-Aldrich Che-
mie GmbH. Endoxan® injection vial of Endoxan 1 
g contains:1.069 g cyclophosphamide monohydrate 
(equivalent to 1 g anhydrous cycphosphamide) as 
the active ingredient was manufactured by industri-
as Farmaceuticas Almirall Prodesfarma S.L.C/San 
Juan no.9,08560 Manlleu/Spain for Baxter Oncol-
ogy Gmbh Kantstrasse 2 D-33790 Halle, Germany. 
All the other chemicals were purchased from stan-
dard local sources. All other reagents used were of 
analytical grade.
Experimental design
Rats  were  randomly  divided  into  seven  groups; 
each is consisting of twenty rats. The groups treated 
as follows. The group I was kept as control, group 
II was given CYP at a single intraperitoneal dose 
of (200 mg/kg body weight) on the first day of the 
experiment according to [12], group III was admin-
istered CYP and Lac, group IV orally administrated 
Lac only (0.5%) in drinking water during the 21 days 
of the experiment according to [13], Group V treated 
with CYP and levamisole. Group VI orally admin-
istrated levamisole at a dose of (2.5 mg/kg body 
weight)  according  to  [14].  Group  VII  was  treated 
with CYP, Lac and levamisole.
Sampling
Animals were anesthetized with diethyl ether then 
were  scarified  at  the  end  of  the  experiment,  two 
separate blood samples were collected from each 
of five rats from each group; the 1st sample was tak-
en in EDTA tubes for measurement of total and dif-
ferential leukocytes count according to [15,16]. 2nd 
sample was taken without anticoagulant and kept 
30 minutes at room temperature then centrifuged 
at 3000 rpm for 10 minutes and the clear serum 
was separated carefully and storage at -20°C for the 
measurement of some immunological parameters.
Evaluation of some immunological parameters
Serum total protein level was determined accord-
ing to Henry et al [17], the serum albumin level was 
determined  by  the  method  of  Doumas  et  al  [18] Mohamed. Effect of lactoferrin on immunostimulant activity of levamisole  50
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using  the  kits  provided  by  Diamond  Diagnostics. 
Regarding to immunological studies, Immunoelec-
trophoresis of serum proteins has been done us-
ing cellulose acetate according to Henry et al [17] , 
lysozyme activity in blood plasma was determined 
by the turbidimetric method of [19] modified by [20] 
and nitric oxide production assay was performed as 
mentioned by [21].
Lysozyme activity
Whole blood samples were centrifuged for 5 min 
at 1000 g to separate blood cells from the serum. 
The serum was diluted 1: 1 with phosphate buffer, 
and 0.1 ml of the solution was placed in the wells 
of microplates. 0.5 ml of Micrococcus lysodeikticus 
bacterial suspension (25 mg bacteria/100 ml phos-
phate buffer) (Sigma Chemical Co.) was added. Ab-
sorbance was measured directly after the addition 
of bacteria (E0) and after 1, 2, 3 and 30 min (final 
E). The final absorbance was subtracted from the 
initial absorbance (E0) to determine lysozyme activ-
ity with the use of a standard curve. The standard 
curve was plotted based on the optical density val-
ues for known lysozyme concentrations.
Nitric oxide assay
NO production was assessed by measuring nitrite 
accumulation in 72h culture supernatants using the 
Griess reaction. Briefly, 100 µl of 0.5% sulfanilamide 
0.05% N-naphtyl-ethylenediamine hydrochloride in 
2.5% H3PO4 (Griess reagent) [22] were added to 
100 µl of supernatants and incubated for 5 min at 
room temperature in the dark. The absorbance was 
then measured at 550 nm and nitrite concentrations 
were  extrapolated  from  a  sodium  nitrite  standard 
curve. 
Statistical analysis
The GRAPHPAD (ISI Software, Philadelphia, PA, 
USA) computer program was used to conduct re-
gression analysis and to plot collected data. Data 
were expressed as means ± standard error (SE). 
Assessment  of  the  results  was  performed  using 
one-way analysis of variance (ANOVA) procedure 
followed by Duncan’s Multiple Range test. The 0.05 
level of probability was used as the criterion for sig-
nificance [23].
RESULTS
Leukogram changes
In the present work, regarding to the result of leuko-
gram, the total leukocytes, neutrophil, lymphocyte 
and monocyte were significantly decreased in CYP 
-  immunosuppressed  group  when  compared  with 
the control group. In CYP- immunosuppressed ani-
mals treated with Lac in GP. (3), levamisole in GP. 
(6) and both Lac and levamisole in GP. (7), these 
parameters  were  improved  when  compared  with 
CYP treated groups. The highest improvement was 
found in the CYP -immunosuppressed rats treated 
with  lactoferrin  and  levamisole  together.  In  lacto-
ferrin,  levamisole  treated  groups,  the  leukogram 
showed  nosignificant  change  in  comparison  with 
control group (Table1).
Table 1. Changes on leukogram (TLC, neutrophils, lymphocyte, eosinophil, basophil and monocyte) in all experimental 
groups
Group TLC
x103/µl
Neutrophils
x103/µl
Lymphocyte
x103/µl
Eosinophil
x103/µl
Basophil
x103/µl
Monocyte
x103/µl
Group I 8.51a ± 0.21 2.90a ± 0.34 4.30a ± 0.12 0.81 ± 0.34 0.06a ± 0.01 0.42ab ± 0.04
Group II 4.45d ± 0.06 1.58b ± 0.08 2.05e ± 0.05 0.70 ± 0.09 0.00b ± 0.00 0.11d ± 0.02
Group III 6.28bc ± 0.16 1.95b ± 0.06 3.23cd ± 0.14 0.78 ± 0.09 0.02b ± 0.00 0.29bc ± 0.04
Group IV 9.17a ± 0.14 3.15a ± 0.33 4.56a ± 0.09 0.89 ± 0.26 0.06a ± 0.01 0.50a ± 0.06
Group V 5.61c ± 0.48 1.69b ± 0.18 2.98d ± 0.25 0.69 ± 0.10 0.01b ± 0.01 0.21cd ± 0.06
Group VI 8.52a ± 0.45 2.95a ± 0.34 4.14ab ± 0.08 0.84 ± 0.38 0.06a ± 0.01 0.40ab ± 0.05
Group VII 6.44b ± 0.38 2.11b ± 0.04 3.70bc ± 0.37 0.81 ± 0.06 0.02b ± 0.00 0.29bc ± 0.04
p value <0.001 0.001 <0.001 0.995 0.002 <0.001
Immunological parameter changes
As shown in Tables (2, 3), significant decrease in 
serum total proteins, albumin, α-globulin, β-globulin 
and γ-globulin levels, Nitric oxide (NO) production 
and lysozyme activity was found in CYP -immuno-
suppressed group when compared with the control Mohamed. Effect of lactoferrin on immunostimulant activity of levamisole  51
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group . In CYP- immunosuppressed animals treated 
with Lac in GP. (3), levamisole in GP. (6) and both 
Lac and levamisole in GP. (7), these parameters 
were improved when compared with CYP-immuno-
suppressed groups. The highest improvement was 
found in the CYP- immunosuppressed rats treated 
with  lactoferrin  and  levamisole  together.  In  lacto-
ferrin, levamisole treated groups, the above men-
tioned parameters showed no significant change in 
comparison with the control group.
Group T. Protein
g/dl
Albumin
g/dl
α-globulin
g/dl
β-globulin
g/dl
γ-globulin
g/dl
Group I 8.89a ± 0.06 4.03a ± 0.05 1.58a ± 0.12 1.41a ± 0.13 1.87a ± 0.06
Group II 4.16d ± 0.38 1.81d ± 0.11 0.97d ± 0.04 0.87c ± 0.04 0.51d ± 0.03
Group III 5.87c ± 0.40 2.61c ± 0.31 1.17cd ± 0.09 1.17ab ± 0.06 0.92cd ± 0.03
Group IV 8.20a ± 0.93 3.22b ± 0.13 1.51a ± 0.04 1.37a ± 0.03 2.10a ± 0.35
Group V 5.54cd ± 0.18 2.56c ± 0.15 1.16cd ± 0.02 1.05bc ± 0.05 0.77d ± 0.03
Group VI 7.60ab ± 0.64 3.06bc ± 0.12 1.49ab ± 0.06 1.28ab ± 0.16 1.77ab ± 0.03
Group VII 6.54bc ± 0.18 2.68c ± 0.07 1.30bc ± 0.07 1.23ab ± 0.05 1.33bc ± 0.13
p value  <0.001 <0.001 <0.001 0.004 <0.001
Table 2.  Changes  on  se-
rum total proteins, albumin, 
α-globulin,  β-globulin  and 
γ-globulin in all experimen-
tal groups
Group
NO
µg/ml p value
ysozyme
mg/l p value
Group I 0.17a ± 0.02
0.086
8.63a ± 0.21
0.002
Group II 0.08b ± 0.01 3.8c ± 0.18
Group III 0.14ab ± 0.03 5.43bc ± 0.32
Group IV 0.18a ± 0.02 7.96a ± 0.99
Group V 0.14ab ± 0.02 5.46bc ± 0.88
Group VI 0.17a ± 0.02 7.96a ± 1.08
Group VII 0.16a ± 0.03 7.43ab ± 0.37
Table 3. Changes on Nitric oxide (NO) production 
and lysozyme activity in all experimental groups
DISCUSSION
Alkylating agents such as cyclophosphamide (CYP) 
were developed and introduced into clinical medi-
cine  in  the  1950s. They  were  primarily  designed 
as anti-cancer drugs [24]. History has shown that 
CYP is one of the most potent immunosuppressive 
drugs. In the present study, we found that CYP in-
duced leukopenia, neutropenia and lymphocytope-
nia in rats, these results parallel to the result of [25] 
who demonstrated that CYP is an effective inhibi-
tor of cell mediated immune response and leads to 
a depletion of lymphocytes in the peripheral blood 
and tissue. Lactoferrin causes an improvement in 
leukogram  in  rats  with  CYP  immunosuppression, 
we agreed with [26] who said that mice treated with 
CYP/Lac have a higher content of functional phago-
cytes  (neutrophils  and  eosinophils)  and  absolute 
cell numbers in circulation. Levamisole is an anthel-
mintic agent that also apparently enhances immune 
responsiveness. It is believed that levamisole medi-
ates the immune function of T-cells and stimulates 
phagocytosis by monocytes [27]. Its immunostimu-
lating effects are greater in immune-compromised 
animals  [28].  According  to  [29],  levamisole  is  a 
useful immunostimulatory agent in cancer patients 
and  other  patients  with  impaired  cellular  immune 
responses. levamisole in our results, showed im-
provement of leukogram in immunosuppressed rats 
, we agreed with the study of [30] which focused 
on levamisole, and found that the lymphocyte and 
monocyte percentage were increased on days 7-14 
after  drug  administration  and  the  results  of  [31] 
which showed a significant increase in neutrophil 
and monocyte levels in levamisole treated animals 
.In addition to these findings , we found that lacto-
ferrin modulate and improved the immunostimula-
tory effect of levamisole.Mohamed. Effect of lactoferrin on immunostimulant activity of levamisole  52
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Cyclophosphamide  exerts  a  direct  impact 
on plasma cells, and it inhibits protein synthesis. 
As shown in Table 2, CYP group showed signifi-
cant decrease of total protein, albumin, α-globulin, 
β-globulin compared with the control group. This re-
sult may be due to decrease protein synthesis as 
a result of liver damage caused by cyclophospha-
mide as mentioned by [32] who found that hypo-
proteinemia was observed in rats administered CYP 
(150 mg/kg) for two days. Also, we found that the 
CYP-immunosuppressed  rats  showed  significant 
decrease in γ-globulins levels, these findings are 
parallel to the results observed by [13]. This may be 
due to the toxic effects of various chemotherapeu-
tic on the liver, including cyclophosphamide, which 
was found to inhibit selected hepatic enzymes as 
described by [33]. CYP exerts a specific and not di-
rectly toxic effect on the cytochrome P450 system, 
which converts cyclophosphamide to active metab-
olites. As the process intensifies (following the ad-
ministration of higher doses of the drug), hepatocyte 
dysfunction is observed, including disturbances in 
the synthesis of selected proteins. A decrease in the 
levels of γ-globulins, may be indirectly caused by 
the inhibition of B cell proliferation by cyclophospha-
mide [33]. In our study, cyclophosphamide decrease 
the activity of lysozyme(which is also a γ-globulin), 
produced by phagocytes and NO production .We 
agreed with Zhao et al [34] who reported a decrease 
in serum lysozyme levels in rats administered CYP 
and the study of [35] that revealed lower levels of 
nitrogen oxide (NO) following the administration of 
cyclophosphamide. The immunomodulatory effects 
of Lactoferrin include influences of the production 
and release of cytokines such as tumor necrosis 
factor-α [36], IL-1β [37], IL-8 [38] and nitric oxide 
[39]. We found that lactoferrin and levamisole el-
evate the levels of total protein and gamma globins 
levels when compared with CYP group, this agreed 
with the result of [13] who found that lactoferrin in-
creased the level of total protein and γ-globulin and 
the result of [31] who said that Levamisole also sig-
nificantly increased the total protein (7-14 days) and 
gamma globins levels.
In conclusion, we have demonstrated for the 
first time that lactoferrin have a synergistic effect to 
modulate and increase the immunostimulatory ef-
fect of levamisole in cyclophosphamide induced im-
munosuppression in rats.
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